Concepedia

Efficacy of exenatide and insulin glargine on nonalcoholic fatty liver disease in patients with type 2 diabetes

Lin Liu, Hongmei Yan, Mingfeng Xia, Lin Zhao, Minzhi Lv, Zhao Nai-qin, Shengxiang Rao, Xiuzhong Yao, Weiyun Wu, Baishen Pan,

Diabetes/Metabolism Research and Reviews · 2020 · 112 citations · 29 references

DOI

Abstract

Both exenatide and insulin glargine reduced LFC in patients with drug-naive T2DM and NAFLD; however, exenatide showed greater reductions in body weight, visceral fat area, liver enzymes, FIB-4, postprandial plasma glucose, and LDL-C.

References

29

Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease

Kerry L. Donnelly, Coleman I. Smith, Sarah Jane Schwarzenberg et al. · Journal of Clinical Investigation · 2005 · 3.4K citations · Full text

Prevalence and Control of Diabetes in Chinese Adults

Yu Xu · JAMA · 2013 · 2.8K citations

Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study

Matthew J. Armstrong, Piers Gaunt, Guruprasad P. Aithal et al. · The Lancet · 2015 · 2K citations · Full text

, , +5

Magnetic Resonance Imaging More Accurately Classifies Steatosis and Fibrosis in Patients With Nonalcoholic Fatty Liver Disease Than Transient Elastography

Kento Imajo, Takaomi Kessoku, Yasushi Honda et al. · Gastroenterology · 2015 · 784 citations · Full text

Glucagon-Like Peptide-1 Receptor Is Present on Human Hepatocytes and Has A Direct Role in Decreasing Hepatic Steatosis in Vitro by Modulating Elements of the Insulin Signaling Pathway

Nitika Gupta, Jamie E. Mells, Richard M. Dunham et al. · Hepatology · 2010 · 503 citations · Full text